In ALL and CML, BCL6 attenuates the survival of leukemic cells from chemotherapy-induced DNA damage through repressing p53 and Arf and by inducing FOXO3a signaling [83,84]. This evidence concerns the gene BCL6 and acute lymphoblastic leukemia.